Klyne

Klyne is an AI-powered drug discovery software company founded in late 2023 by CEO Zachary Lawrence, a mathematician and computer scientist with prior biotech investment experience. The company builds proprietary AI models — including the SPARC model — to predict binding affinity between drug candidates and target proteins, enabling early-stage drug discovery at a fraction of traditional costs. Klyne's platform analyzes trillions of compounds to identify chemical structures likely to bind to a given protein, offering both self-serve software licenses and a white-glove managed service for companies lacking in-house in silico expertise. Operating on a pay-as-you-go model rather than high upfront subscriptions, Klyne democratizes access to advanced drug discovery tools for startups, academic researchers, and large pharma enterprises alike.